Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OCS 05

Drug Profile

OCS 05

Alternative Names: ACT-01; BN-201; G-79; OCS-05

Latest Information Update: 15 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bionure
  • Developer Bionure; Oculis Pharma
  • Class Anti-inflammatories; Antiglaucomas; Eye disorder therapies; Neuroprotectants; Peptides; Small molecules
  • Mechanism of Action Brain derived neurotrophic factor agonists; Insulin-like growth factor I stimulants; Neuron modulators; Serum-glucocorticoid regulated kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Optic neuritis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Optic neuritis
  • Preclinical Glaucoma; Neurotrophic keratopathy
  • No development reported Multiple sclerosis; Neuromyelitis optica

Most Recent Events

  • 08 May 2024 Oculis Pharma completes enrolment in its phase II ACUITY trial for Optic neuritis in France (IV) (NCT04762017) (EudraCT2020-003147-29)
  • 18 Mar 2024 Oculis Pharma anticipates to submit IND application in USA, in 2024
  • 19 Jul 2023 OCS 05 is still in preclinical development for Glaucoma in Spain (IV, Infusion) (Oculis Pharma Pippeline, July 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top